Chinese mRNA vaccine developer Suzhou Abogen Biosciences Co Ltd has raised as much as $300 million in its Series C+ round of funding, per an announcement.
SoftBank Vision Fund alongside returning investor 5Y Capital jointly led the funding.
Continue reading this story with a subscription to DealStreetAsia.
SubscribeAlready a Subscriber? Log in
Contact us for corporate subscriptions at subs@delastreetasia.com
